BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31634178)

  • 1. Does A Longer Waiting Period After Neoadjuvant Radio-chemotherapy Improve the Oncological Prognosis of Rectal Cancer?: Three Years' Follow-up Results of the Greccar-6 Randomized Multicenter Trial.
    Lefèvre JH; Mineur L; Cachanado M; Denost Q; Rouanet P; de Chaisemartin C; Meunier B; Mehrdad J; Cotte E; Desrame J; Karoui M; Benoist S; Kirzin S; Berger A; Panis Y; Piessen G; Saudemont A; Prudhomme M; Peschaud F; Dubois A; Loriau J; Tuech JJ; Meurette G; Lupinacci R; Goasguen N; Creavin B; Simon T; Parc Y;
    Ann Surg; 2019 Nov; 270(5):747-754. PubMed ID: 31634178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6).
    Lefevre JH; Mineur L; Kotti S; Rullier E; Rouanet P; de Chaisemartin C; Meunier B; Mehrdad J; Cotte E; Desrame J; Karoui M; Benoist S; Kirzin S; Berger A; Panis Y; Piessen G; Saudemont A; Prudhomme M; Peschaud F; Dubois A; Loriau J; Tuech JJ; Meurette G; Lupinacci R; Goasgen N; Parc Y; Simon T; Tiret E
    J Clin Oncol; 2016 Nov; 34(31):3773-3780. PubMed ID: 27432930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
    Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
    Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
    J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial.
    Rullier E; Vendrely V; Asselineau J; Rouanet P; Tuech JJ; Valverde A; de Chaisemartin C; Rivoire M; Trilling B; Jafari M; Portier G; Meunier B; Sieleznieff I; Bertrand M; Marchal F; Dubois A; Pocard M; Rullier A; Smith D; Frulio N; Frison E; Denost Q
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):465-474. PubMed ID: 32043980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis.
    Sung S; Kim SH; Lee JH; Nam TK; Jeong S; Jang HS; Song JH; Lee JW; Bae JM; Lee JH
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):647-653. PubMed ID: 28581407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.
    García-Albéniz X; Gallego R; Hofheinz RD; Fernández-Esparrach G; Ayuso-Colella JR; Bombí JA; Conill C; Cuatrecasas M; Delgado S; Ginés A; Miquel R; Pagés M; Pineda E; Pereira V; Sosa A; Reig O; Victoria I; Feliz L; María de Lacy A; Castells A; Burkholder I; Hochhaus A; Maurel J
    World J Gastroenterol; 2014 Nov; 20(42):15820-9. PubMed ID: 25400468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
    Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
    J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
    Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
    BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of neoadjuvant chemoradiation in MRI staged locally advanced rectal cancer: Retrospective analysis of 123 Chinese patients.
    Lee SF; Chiang CL; Lee FAS; Wong YW; Poon CM; Wong FCS; Tung SY
    J Formos Med Assoc; 2018 Sep; 117(9):825-832. PubMed ID: 29100742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.
    Lin Y; Lin H; Xu Z; Zhou S; Chi P
    J Invest Surg; 2019 Nov; 32(7):679-687. PubMed ID: 30215538
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictive factors of disease-free survival after complete pathological response to neoadjuvant radiotherapy for rectal adenocarcinoma: retrospective case series.
    Souadka A; Majbar MA; Benkabbou A; Serji B; Souiki T; Bouchentouf SM; Abid M; El Khannousi B; El Harroudi T; El Malki HO; Raiss M; Ifrine L; Mazaz K; Zentar A; Mohsine R; Souadka A; Belkouchi A; Ahallat M; Hrora A;
    BMC Cancer; 2019 Oct; 19(1):1008. PubMed ID: 31660903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
    Seddik Y; Brahmi SA; Afqir S
    Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience.
    Nguyen P; Wuthrick E; Chablani P; Robinson A; Simmons L; Wu C; Arnold M; Harzman AE; Husain S; Schmidt C; Abdel-Misih S; Bekaii-Saab T; Chakravarti A; Williams TM
    Am J Clin Oncol; 2018 Feb; 41(2):140-146. PubMed ID: 26535992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy.
    Depypere L; Moons J; Lerut T; De Hertogh G; Peters C; Sagaert X; Coosemans W; Van Veer H; Nafteux P
    Dis Esophagus; 2018 Feb; 31(2):. PubMed ID: 29036407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Completely Abdominal Approach Laparoscopic Partial Intersphincteric Resection After Neoadjuvant Chemoradiation for Initial cT3 Juxta-Anal Rectal Cancer.
    Huang S; Huang Y; Chi P; Lin H; Lu X; Xu Z; Sun Y; Wang X
    J Laparoendosc Adv Surg Tech A; 2019 Jun; 29(6):809-816. PubMed ID: 30596539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.